Research has shown inconsistent associations between women’s empowerment and sexual and reproductive health (SRH) in sub-Saharan Africa (SSA), pointing to a lack of salient measures in this context. A novel measure provides an opportunity to explore different facets of SRH empowerment in SSA. Methods We used five national surveys among women 15-49 years conducted between 2019-2020 in Kenya (n=5,504), Uganda (n=2,273), Cote d’Ivoire (n=2,329), Burkina Faso (n=4,135), and Niger (n=2,228). Two measures of contraceptive and sexual empowerment were combined into a four-category SRH empowerment measure to identify the opportunity structures associated with SRH empowerment using multinomial logistic regression modeling.  Results SRH empowerment was lowest in Niger and highest in Kenya. Between 15.0% and 21.7% of participants had more sexual but less contraceptive empowerment than their peers, while the opposite was true for 15.4% to 20.4% of participants. Education increased overall SRH empowerment or sexual empowerment alone in all sites and contraceptive empowerment alone in Kenya. Wealth increased overall SRH empowerment or sexual empowerment alone in three sites. Parity increased overall empowerment or contraceptive empowerment alone in all sites but decreased sexual empowerment alone in Uganda. Finally, healthcare provider contact increased overall and contraceptive empowerment in four sites while family planning media messages increased overall empowerment in two sites. Conclusion This study confirms the multidimensional nature of SRH empowerment, which varies by country, domain, and by women’s parity and social capital. Longitudinal research is needed to comprehend how women gain or lose SRH empowerment and how empowerment predicts SRH outcomes.

The authors have declared no competing interest.

This study was conducted with support received from the Bill & Melinda Gates Foundation through a grants received by the Bill & Melinda Gates Institute for Population and Reproductive Health for the Performance Monitoring and Accountability 2020 (OPP1079004).

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

PMA has been approved by the Institutional Review Board at the Johns Hopkins Bloomberg School of Public Health (IRB14702 MOD18860 MOD3903 MOD4748)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes